A Phase 2 interventional study of enfortumab vedotin and pembrolizumab in Locally Advanced or Metastatic Malignant Solid Tumors, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 39 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 57th largest by enrollment of the 605 interventional ones that give a count, is one of 42 that started in 2020, is one of 191 in phase 2, reaches primary completion later than 30 of the 263 other live ones, and was the 352nd registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 18–75 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
Stephen Shiao · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 300 · Phase 3 29
First in 2001; this study’s year is marked. 42 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 329 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 605 interventional studies, 90 across the 38 observational. Of the 338 that completed or were terminated, 179 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
319 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Astellas Pharma Inc has 1 study filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
93 of the studies in Triple Negative Breast Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
Add all 93 to your calendar (.ics) → With an account.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.
This study will consist of 3 periods: screening/baseline, treatment and follow-up.
Screening/baseline period will take place up to 28 days prior to the first dose of study treatment.
In the treatment period, starting at cycle 1, participants in cohorts 1 to 8 will receive enfortumab vedotin on days 1, 8, and 15 every 28-day cycle until one of the treatment discontinuation criteria are met. participants in cohort 9 will receive enfortumab vedotin on days 1, 8, and pembrolizumab on day 1 of every 21-day cycle until one of the treatment discontinuation criteria are met. Disease assessment will be performed at screening/baseline and repeated every 8 weeks (56 days ± 7 days) for cohorts 1 to 8 and first assessment at week 9 and thereafter every 6 weeks (42 days ± 7 days) for cohort 9 from the first dose of study treatment throughout the study until the participant has radiologically confirmed disease progression, initiates a new subsequent anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.
Participants who discontinue study treatment for reasons other than radiologically-confirmed disease progression by RECIST Version 1.1 will enter into a post treatment follow-up period and continue to receive imaging scans every 8 weeks (56 days ± 7 days) for cohorts 1 to 8 and for cohort 9 first scan will be performed at 9 week and thereafter every 6 weeks (42 days ± 7 days) until the subject has radiologically confirmed disease progression (for cohort 9 confirmed progressive disease [iCPD] per modified RECIST 1.1 for immune-based therapeutics [iRECIST]), initiates a new anticancer therapy, dies, withdraws consent, is lost to follow-up or the study closes, whichever occurs first.
After 1 year on study treatment, the frequency of disease assessment will be reduced to every 12 weeks (84 days ± 7 days) for cohorts 1 to 8.
After 18 months on study treatment, the frequency of disease assessment will be reduced to every 9 weeks (63 days ± 7 days) for cohort 9.
Participants in cohorts 1to 8 who discontinue study treatment for reasons other than radiologically-confirmed disease progression by RECIST Version 1.1 will enter into a post treatment follow-up period and continue to receive imaging scans every 8 weeks (56 days ± 7 days).
Participants in cohort 9 who discontinue study treatment for reasons other than radiologically confirmed disease progression per iRECIST will enter into a post treatment follow-up period and have physical exams, ECOG and disease assessments every 6 weeks (± 7 days) up to 18 months after first dose, then every 9 weeks (± 7 days) until the subject has radiologically confirmed disease progression per iRECIST.
After radiologically-confirmed disease progression or initiation of subsequent anticancer therapy, whichever occurs first, participants will be contacted every 12 weeks in the long-term follow-up period for survival status until death, withdrawal of consent, lost to follow-up or study closure, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained ≥ 28 days after any blood transfusion.
Disease Specific Inclusion Criteria:
Cohort 1: HR+/- breast cancer
Subject must have received a taxane or anthracycline in the , adjuvant or incurable, locally advanced or metastatic setting.
Cohort 2: triple negative breast cancer (TNBC)
Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.
Cohort 3: squamous non-small cell lung cancer (NSCLC)
Subject has histologically or cytologically-confirmed squamous NSCLC.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
Cohort 4: non-squamous non-small cell lung cancer
Subject has histologically- or cytologically-confirmed non-squamous NSCLC.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
Cohort 5: or later head and neck cancer
Subject has histologically- or cytologically-confirmed head and neck cancer.
Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
Cohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma
Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received > 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.
Cohort 9: 1L HNSCC
Subject has histologically- or cytologically-confirmed head and neck squamous cell carcinoma.
a. Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 9.
Exclusion Criteria:
For All Cohorts:
Subject has active central nervous system (CNS) . Subjects with treated are permitted on study if all the following are true:
Cohort 9: 1L HNSCC
Active disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or drugs).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8. GEJ= gastroesophageal junction
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
Drug: enfortumab vedotin
Participants will receive enfortumab vedotin as an IV infusion on days 1 and 8 of each 21-day cycle. Pembrolizumab will be administered as an IV infusion on day 1 of each 21-day cycle.
Drug: enfortumab vedotin · Drug: pembrolizumab
intravenous (IV) infusion
Also known as: ASG-22CE
IV infusion
Also known as: KEYTRUDA®
Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment
Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).
Time frame: Up to 20.04 months
Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment
Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).
Time frame: Up to 12.85 months
Cohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment
DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented progressive disease (PD) per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.
Time frame: Up to 20.04 months
Cohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment
DCR was defined as the percentage of participants whose Best Overall Response (BOR) was confirmed CR or PR or stable disease (SD) (≥ 7 weeks).
Time frame: Up to 22 months
Cohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment
PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.
Time frame: Up to 22 months
Cohorts 1-8: Overall Survival (OS)
OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.
Time frame: Up to 34 months
Cohorts 1-8: Number of Participants With Treatment-emergent Adverse Events (AEs)
A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by a TEAE); or other medically important events.
Time frame: Up to end of treatment + 30 days (32 months)
Cohort 9: DOR Per RECIST V.1.1 Per Investigator Assessment
DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.
Time frame: Up to 12.85 months
Cohort 9: DCR Per RECIST V1.1 Per Investigator Assessment
DCR was defined as the percentage of participants whose BOR is confirmed CR or PR or SD (≥ 7 weeks).
Time frame: Up to 15 months
Cohort 9: PFS Per RECIST V1.1 by Investigator Assessment
PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.
Time frame: Up to 15 months
Cohort 9: OS
OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.
Time frame: Up to 15.4 months
Cohort 9: Number of Participants With TEAEs
A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by an AE); or other medically important events.
Time frame: Up to end of treatment + 30 day (15 months)
Participants of either gender, over 18 years of age, who were either previously treated for locally advanced or metastatic malignant solid tumours (Cohorts 1-8) or who had no previous treatment (Cohort 9), were enrolled in this study. Cohort 9 enrolment began after protocol amendment 5 was implemented.
| Milestone | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC |
|---|---|---|---|---|---|---|---|---|
| Started | 45 | 42 | 23 | 45 | 46 | 42 | 45 | 41 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 45 | 42 | 23 | 45 | 46 | 42 | 45 | 41 |
| Withdrew: Did not receive any amount of study intervention | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 2 | 2 | 4 | 8 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 4 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 36 | 30 | 20 | 33 | 37 | 34 | 39 | 9 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing | 4 | 4 | 0 | 4 | 4 | 0 | 1 | 30 |
Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).
| Percentage of participants | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC |
|---|---|---|---|---|---|---|---|
| Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment | 15.6 (6.49 to 29.46) | 19.0 (8.60 to 34.12) | 4.3 (0.11 to 21.95) | 16.3 (6.81 to 30.70) | 23.9 (12.59 to 38.77) | 9.5 (2.66 to 22.62) | 18.2 (8.19 to 32.71) |
Confirmed ORR was defined as the percentage of participants whose objective response was confirmed as CR or PR according to RECIST V1.1 per investigator assessment, using exact method based on binomial distribution (Clopper-Pearson).
| Percentage of participants | Cohort 9: HNSCC |
|---|---|
| Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment | 39.0 (24.20 to 55.50) |
DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented progressive disease (PD) per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.
| Months | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC |
|---|---|---|---|---|---|---|---|
| Cohorts 1-8: Duration of Resonse (DOR) Per RECIST V.1.1 Per Investigator Assessment | 7.23 (3.52 to 7.23) | 3.78 (1.87 to 3.94) | 3.71 (NA to NA) | 10.15 (9.69 to 10.38) | 9.43 (2.53 to NA) | 10.32 (1.64 to 10.32) | 3.88 (2.33 to 7.39) |
DCR was defined as the percentage of participants whose Best Overall Response (BOR) was confirmed CR or PR or stable disease (SD) (≥ 7 weeks).
| Percentage of participants | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC |
|---|---|---|---|---|---|---|---|
| Cohorts 1-8: Disease Control Rate (DCR) Per RECIST V1.1 Per Investigator Assessment | 51.1 (35.77 to 66.30) | 57.1 (40.96 to 72.28) | 65.2 (42.73 to 83.62) | 67.4 (51.46 to 80.92) | 56.5 (41.11 to 71.07) | 47.6 (32.00 to 63.58) | 45.5 (30.39 to 61.15) |
PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.
| Months | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC |
|---|---|---|---|---|---|---|---|
| Cohorts 1-8: Progression Free Survival (PFS) Per RECIST V1.1 Per Investigator Assessment | 5.39 (3.35 to 5.68) | 3.52 (2.10 to 4.63) | 3.52 (1.91 to 5.42) | 4.11 (2.76 to 5.72) | 3.94 (2.79 to 4.67) | 3.06 (1.77 to 3.71) | 2.10 (1.87 to 3.71) |
OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.
Results for this outcome have not been posted.
A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by a TEAE); or other medically important events.
| Participants | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC |
|---|---|---|---|---|---|---|---|
| TEAEs | 45 | 42 | 22 | 42 | 45 | 42 | 43 |
| Serious TEAEs | 12 | 9 | 8 | 16 | 22 | 14 | 12 |
DOR was defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD per RECIST V1.1 or death due to any cause, whichever occurs first. DOR was only calculated for participants achieving a confirmed CR or PR, based on Kaplan-Meier estimate.
| Months | Cohort 9: HNSCC |
|---|---|
| Cohort 9: DOR Per RECIST V.1.1 Per Investigator Assessment | NA (5.78 to NA) |
DCR was defined as the percentage of participants whose BOR is confirmed CR or PR or SD (≥ 7 weeks).
| Percentage of participants | Cohort 9: HNSCC |
|---|---|
| Cohort 9: DCR Per RECIST V1.1 Per Investigator Assessment | 75.6 (59.70 to 87.64) |
PFS was defined as the time from start of study intervention to first documentation of objective tumor progression or death due to any cause, whichever comes first, based on Kaplan-Meier estimate.
| Months | Cohort 9: HNSCC |
|---|---|
| Cohort 9: PFS Per RECIST V1.1 by Investigator Assessment | 5.06 (3.45 to NA) |
OS was defined as the time from start of study treatment to date of death due to any cause, based on Kaplan-Meier estimate. In the absence of confirmed death, OS was censored at the last date the participant was known to be alive.
Results for this outcome have not been posted.
A TEAE is any untoward medical occurrence in a participant administered enfortumab vedotin, and which does not necessarily have to have a causal relationship with this treatment. A TEAE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of enfortumab vedotin whether or not considered related to the enfortumab vedotin. A TEAE is considered "serious" if the event: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly or birth defect; requires inpatient hospitalization (except for planned procedures) or leads to prolongation of hospitalization (except if prolongation of planned hospitalization is not caused by an AE); or other medically important events.
Results for this outcome have not been posted.
Collected over Cohorts 1-8: All-cause mortality: up to 34 months; AEs: up to end of treatment + 30 days (32 months). Cohort 9: All-cause mortality: up to 15 months; AEs: up to end of treatment + 30 days (15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: HR+/HER2- Breast Cancer | 36/45 (80%) | 12/45 (26.7%) | 44/45 (97.8%) |
| Cohort 2: TNBC Cancer | 30/42 (71.4%) | 9/42 (21.4%) | 42/42 (100%) |
| Cohort 3: Squamous NSCLC | 20/23 (87%) | 8/23 (34.8%) | 21/23 (91.3%) |
| Cohort 4: Non-squamous NSCLC | 33/45 (73.3%) | 16/43 (37.2%) | 42/43 (97.7%) |
| Cohort 5: Head and Neck Cancer | 38/46 (82.6%) | 22/46 (47.8%) | 42/46 (91.3%) |
| Cohort 7: EAC | 34/42 (81%) | 14/42 (33.3%) | 41/42 (97.6%) |
| Cohort 8: ESCC | 39/45 (86.7%) | 12/44 (27.3%) | 42/44 (95.5%) |
| Cohort 9: HNSCC | 10/41 (24.4%) | 21/41 (51.2%) | 39/41 (95.1%) |
| Event | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/45 | 0/42 | 2/23 | 1/43 | 0/46 | 0/42 | 1/44 | 0/41 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 0/42 | 0/23 | 0/43 | 0/46 | 0/42 | 1/44 | 3/41 |
| SyncopeNervous system disorders | 0/45 | 0/42 | 0/23 | 0/43 | 0/46 | 0/42 | 0/44 | 3/41 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/45 | 0/42 | 1/23 | 2/43 | 0/46 | 0/42 | 0/44 | 3/41 |
| Abdominal painGastrointestinal disorders | 2/45 | 0/42 | 0/23 | 0/43 | 1/46 | 2/42 | 0/44 | 2/41 |
| SepsisInfections and infestations | 2/45 | 1/42 | 0/23 | 2/43 | 0/46 | 0/42 | 0/44 | 2/41 |
| Acute kidney injuryRenal and urinary disorders | 0/45 | 0/42 | 1/23 | 1/43 | 0/46 | 1/42 | 0/44 | 2/41 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/45 | 1/42 | 0/23 | 0/43 | 1/46 | 0/42 | 0/44 | 2/41 |
| Disease progressionGeneral disorders | 0/45 | 0/42 | 0/23 | 0/43 | 0/46 | 2/42 | 0/44 | 0/41 |
| Alanine aminotransferase increasedInvestigations | 1/45 | 2/42 | 0/23 | 0/43 | 0/46 | 0/42 | 0/44 | 0/41 |
| Event | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC |
|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 21/45 | 13/42 | 12/23 | 16/43 | 14/46 | 15/42 | 9/44 | 19/41 |
| Decreased appetiteMetabolism and nutrition disorders | 9/45 | 11/42 | 11/23 | 13/43 | 10/46 | 16/42 | 13/44 | 9/41 |
| PruritusSkin and subcutaneous tissue disorders | 20/45 | 15/42 | 8/23 | 17/43 | 7/46 | 17/42 | 13/44 | 16/41 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 19/45 | 14/42 | 6/23 | 16/43 | 8/46 | 12/42 | 13/44 | 10/41 |
| Peripheral sensory neuropathyNervous system disorders | 7/45 | 11/42 | 6/23 | 17/43 | 13/46 | 6/42 | 5/44 | 9/41 |
| AlopeciaSkin and subcutaneous tissue disorders | 11/45 | 13/42 | 9/23 | 16/43 | 13/46 | 15/42 | 8/44 | 12/41 |
| NauseaGastrointestinal disorders | 17/45 | 15/42 | 8/23 | 15/43 | 8/46 | 13/42 | 9/44 | 13/41 |
| DiarrhoeaGastrointestinal disorders | 12/45 | 5/42 | 8/23 | 12/43 | 11/46 | 12/42 | 2/44 | 15/41 |
| ConstipationGastrointestinal disorders | 10/45 | 6/42 | 6/23 | 9/43 | 7/46 | 15/42 | 8/44 | 8/41 |
| DysgeusiaNervous system disorders | 13/45 | 13/42 | 8/23 | 14/43 | 9/46 | 14/42 | 11/44 | 6/41 |
Full Analysis Set (FAS): All enrolled participants who received any amount of study intervention.
| Age, Continuous(Years) | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 57.5 ± 9.8 | 53.5 ± 11.3 | 65.5 ± 8.5 | 65.7 ± 10.4 | 63.2 ± 9.5 | 59.5 ± 12 | 64.9 ± 9 | 66.5 ± 7.9 | 61.8 ± 10.8 |
| Sex: Female, Male(Participants) | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 45 | 42 | 10 | 21 | 6 | 12 | 8 | 10 | 154 |
| Male | 0 | 0 | 13 | 22 | 40 | 30 | 36 | 31 | 172 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 0 | 1 | 0 | 4 | 0 | 2 | 12 |
| Not Hispanic or Latino | 40 | 40 | 22 | 41 | 43 | 37 | 40 | 38 | 301 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 1 | 13 |
| Race (NIH/OMB)(Participants) | Cohort 1: HR+/HER2- Breast Cancer | Cohort 2: TNBC Cancer | Cohort 3: Squamous NSCLC | Cohort 4: Non-squamous NSCLC | Cohort 5: Head and Neck Cancer | Cohort 7: EAC | Cohort 8: ESCC | Cohort 9: HNSCC | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 7 | 11 | 3 | 9 | 15 | 11 | 38 | 9 | 103 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 1 | 2 | 1 | 0 | 0 | 2 | 12 |
| White | 32 | 25 | 17 | 31 | 27 | 29 | 2 | 29 | 192 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 2 | 3 | 2 | 1 | 3 | 2 | 4 | 1 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Mar 2020 to primary completion in Feb 2025, 59 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 59 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enfortumab vedotin
Triple Negative Breast Neoplasms →
Astellas Pharma Global Development, Inc. →